利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.02 秒)

    NOVEL ANTIBODIES AGAINST FACTOR XI AND USES THEREOF
    3.
    发明公开
    NOVEL ANTIBODIES AGAINST FACTOR XI AND USES THEREOF 审中-公开

    公开(公告)号：EP4413996A3

    公开(公告)日：2024-10-23

    申请号：EP24166025.7

    申请日：2017-09-18

    申请人： Aronora, Inc.

    发明人： WILMEN, Andreas ,  BUCHMÜLLER, Anja ,  TUCKER, Erik

    IPC分类号： C07K16/36 ,  A61P7/02 ,  A61K39/00

    摘要： The present invention in general relates to novel binding molecules, in particular antibodies and compositions and kits comprising the same. Said binding molecules are capable of binding to human Factor XI and hence envisaged to be particularly useful in inhibiting thrombosis without compromising hemostasis. The binding molecules, compositions and kits provided herein are therefore inter alia intended for treatment of thrombosis-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of the invention, vectors comprising said polynucleotides and host cells for producing the polynucleotides are provided herein.

    FUSION POLYPEPTIDES AND USES THEREOF
    4.
    发明公开
    FUSION POLYPEPTIDES AND USES THEREOF 有权
    FUSIONSPOLYPEPTIDE UND VERWENDUNGEN DAVON

    公开(公告)号：EP2938630A1

    公开(公告)日：2015-11-04

    申请号：EP13814133.8

    申请日：2013-12-20

    申请人： Bayer Pharma Aktiengesellschaft

    发明人： WILMEN, Andreas ,  LEINEWEBER, Kirsten ,  SCHEERER, Nina Alexandra ,  JÖRISSEN, Hannah

    IPC分类号： C07K14/64 ,  C07K19/00

    CPC分类号： C07K14/64 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30

    摘要： The present invention provides Relaxin fusion polypeptides with extended half-life. Thereby, the half-life extending parts are either the Fc moiety of the human IgG2 or of the human IgG4. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.

    摘要翻译： 本发明提供具有延长的半衰期的松弛素融合多肽。 因此，半衰期延长部分是人IgG2或人IgG4的Fc部分。 此外，本发明提供了编码前述融合多肽的核酸序列，含有该融合多肽的载体，药物组合物和这种融合多肽的医学应用。